查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球精神分裂症治療市場 - 全球產業分析、規模、份額、成長、趨勢、預測 (2031) - 按產品類型、按分銷管道、按地區
市場調查報告書
商品編碼
1410585

全球精神分裂症治療市場 - 全球產業分析、規模、份額、成長、趨勢、預測 (2031) - 按產品類型、按分銷管道、按地區

Schizophrenia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
出版日期: | 出版商: Fairfield Market Research | 英文 185 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

精神分裂症的特徵是對現實的異常解釋，導致各種行為變化，包括幻覺和妄想。精神分裂症的治療是持續的，藥物治療透過調節大腦中的多巴胺水平來控制患者的行為，發揮至關重要的作用。

抗精神病藥，尤其是第二代抗精神病藥，通常被處方，因為它們比第一代抗精神病藥副作用更少。除了藥物治療外，個別治療、社交技能治療等治療也被用來改善精神分裂症患者的生活品質。

根據世界衛生組織 (WHO) 統計，全球約有 5000 萬人患有精神分裂症。儘管盛行率正在下降，但該疾病的診斷率和處方率持續上升，預計精神分裂症治療藥物將顯著增長。

診斷率的增加是由於尋求治療的患者數量的增加。自 1970 年推出第一種治療精神分裂症的非典型抗精神病藥物以來，由於與非典型抗精神病藥物相關的副作用減少，對治療的追求顯著增加。

精神分裂症藥物市場的主要參與者正在積極進入商業化和研究合作夥伴關係，以抓住機會。事實證明，合作和夥伴關係比併購更有效，並且能產生即時的正面影響。精神分裂症藥物製造商也正在探索新興市場作為創造收入途徑。

該報告考察了全球精神分裂症治療市場，並提供了市場概況，包括按產品類型、分銷管道、地區劃分的趨勢以及進入市場的公司的競爭趨勢。

目錄

第一章執行摘要

第二章市場概況

  • 市場定義與細分
  • 市場動態
  • 價值鏈分析
  • 波特五力分析
  • COVID-19 影響分析
  • 烏克蘭與俄羅斯衝突的影響
  • 經濟概況
  • PESTLE分析

第三章 2018-2031年全球精神分裂症治療市場前景

  • 全球精神分裂症治療市場展望，按產品類型、價值（百萬美元），2018-2031
  • 全球精神分裂治療市場展望，按分銷管道劃分，價值（百萬美元），2018-2031
  • 全球精神分裂症治療市場展望，按地區，價值（百萬美元），2018-2031

第四章 2018-2031 年北美精神分裂症治療市場展望

第五章歐洲精神分裂症治療市場展望，2018-2031

第六章 2018-2031 年亞太地區精神分裂症治療市場展望

第七章 2018-2031 年拉丁美洲精神分裂症治療市場展望

第八章 2018-2031年中東和非洲精神分裂症治療市場展望

第9章 競爭格局

  • 按製造商和分銷管道劃分的熱圖
  • 2023 年公司市場份額分析
  • 競爭力儀表板
  • 公司簡介
    • Johnson & Johnson Services, Inc.
    • Bristol-Myers Squibb Company
    • Otsuka Holdings Co., Ltd
    • AstraZeneca
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Eli Lilly and Company
    • Alkermes
    • Vanda Pharmaceuticals
    • ALLERGAN
    • Pfizer Inc.

第10章附錄

簡介目錄

Schizophrenia, a chronic disorder that profoundly impacts individuals' lives, is characterized by an abnormal interpretation of reality and leads to various behavioral changes, including hallucinations and delusions. Schizophrenia treatment is an ongoing journey, with medications playing a pivotal role in controlling patients' behavior by regulating dopamine levels in the brain.

Advancements in Treatment

Antipsychotic medications, particularly second-generation antipsychotics, are commonly prescribed due to their reduced side effects compared to first-generation counterparts. In addition to medication, schizophrenia is also addressed through therapies such as individual therapy and social skill therapy, enhancing the quality of life for individuals living with schizophrenia.

Global Market Insights

A comprehensive research report on the global schizophrenia treatment market explores various therapies and their market scenarios across different regions. The report delves into trends, drivers, challenges, and opportunities shaping the landscape. According to the research, the global schizophrenia treatment market is poised for robust expansion in the coming years.

The Burden of Schizophrenia

According to the World Health Organization, approximately 50 million people worldwide are affected by schizophrenia. Despite a declining prevalence rate, the diagnosis and prescription rates for this disorder continue to rise, creating substantial growth prospects for schizophrenia treatment.

The increasing rate of diagnosis can be attributed to a growing number of patients seeking treatment. Since the introduction of the first atypical antipsychotic treatment for schizophrenia in 1970, the pursuit of treatment has significantly increased, thanks to the reduced side effects associated with atypical psychotic medications.

Collaborative Efforts Drive Market Growth

Key players in the schizophrenia treatment market are actively forging commercialization and research alliances to seize opportunities. Collaborations and partnerships have proven to be more effective than mergers and acquisitions, yielding immediate positive impacts. Manufacturers of schizophrenia medications are also exploring emerging markets as avenues for revenue generation.

Atypical Antipsychotics Take the Lead

Among the various medications available for schizophrenia, atypical antipsychotic treatment, a second-generation medication, stands out for its effectiveness and fewer side effects. The atypical antipsychotics segment is projected to experience high growth during the forecast period.

Miscellaneous antipsychotic agents, including lithium, pimozide, molindone, haloperidol, and loxapine, are also gaining traction. Physicians often opt for haloperidol and lithium due to their effectiveness and competitive pricing. The miscellaneous antipsychotic agents segment is expected to expand at a value CAGR of 6.1% throughout the assessment period.

As the global schizophrenia treatment market continues to evolve, it holds the promise of transforming the lives of individuals affected by this challenging disorder. The focus on innovative treatments and collaborative efforts reflects the commitment of stakeholders to improve the well-being and outlook for those living with schizophrenia.

Schizophrenia Treatment Market Segmentation:

By Product Type

  • Atypical Antipsychotics
  • Phenothiazine Antipsychotics
  • Thioxanthenes
  • Miscellaneous Antipsychotic Agents

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • E-Commerce

By Region

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific Excluding Japan (APEJ)
  • Japan
  • Middle East and Africa (MEA)

Table of Contents

1. Executive Summary

  • 1.1. Global Schizophrenia Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Schizophrenia Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Atypical Antipsychotics
      • 3.1.1.2. Phenothiazine Antipsychotics
      • 3.1.1.3. Thioxanthenes
      • 3.1.1.4. Miscellaneous Antipsychotic Agents
  • 3.2. Global Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Hospital Pharmacies
      • 3.2.1.2. Drug Stores
      • 3.2.1.3. Retail Pharmacies
      • 3.2.1.4. E-Commerce
  • 3.3. Global Schizophrenia Treatment Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Schizophrenia Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Atypical Antipsychotics
      • 4.1.1.2. Phenothiazine Antipsychotics
      • 4.1.1.3. Thioxanthenes
      • 4.1.1.4. Miscellaneous Antipsychotic Agents
  • 4.2. North America Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Hospital Pharmacies
      • 4.2.1.2. Drug Stores
      • 4.2.1.3. Retail Pharmacies
      • 4.2.1.4. E-Commerce
    • 4.2.2. BPS Analysis/Market Attractiveness Analysis
  • 4.3. North America Schizophrenia Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 4.3.1.2. U.S. Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 4.3.1.3. Canada Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 4.3.1.4. Canada Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Schizophrenia Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Atypical Antipsychotics
      • 5.1.1.2. Phenothiazine Antipsychotics
      • 5.1.1.3. Thioxanthenes
      • 5.1.1.4. Miscellaneous Antipsychotic Agents
  • 5.2. Europe Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Hospital Pharmacies
      • 5.2.1.2. Drug Stores
      • 5.2.1.3. Retail Pharmacies
      • 5.2.1.4. E-Commerce
    • 5.2.2. BPS Analysis/Market Attractiveness Analysis
  • 5.3. Europe Schizophrenia Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 5.3.1.2. Germany Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.3.1.3. U.K. Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 5.3.1.4. U.K. Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.3.1.5. France Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 5.3.1.6. France Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.3.1.7. Italy Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 5.3.1.8. Italy Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.3.1.9. Turkey Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 5.3.1.10. Turkey Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.3.1.11. Russia Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 5.3.1.12. Russia Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.3.1.13. Rest of Europe Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 5.3.1.14. Rest of Europe Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Schizophrenia Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Atypical Antipsychotics
      • 6.1.1.2. Phenothiazine Antipsychotics
      • 6.1.1.3. Thioxanthenes
      • 6.1.1.4. Miscellaneous Antipsychotic Agents
  • 6.2. Asia Pacific Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Hospital Pharmacies
      • 6.2.1.2. Drug Stores
      • 6.2.1.3. Retail Pharmacies
      • 6.2.1.4. E-Commerce
    • 6.2.2. BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Schizophrenia Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 6.3.1.2. China Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.3.1.3. Japan Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 6.3.1.4. Japan Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.3.1.5. South Korea Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 6.3.1.6. South Korea Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.3.1.7. India Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 6.3.1.8. India Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.3.1.9. Southeast Asia Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 6.3.1.10. Southeast Asia Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.3.1.11. Rest of Asia Pacific Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 6.3.1.12. Rest of Asia Pacific Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Schizophrenia Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Atypical Antipsychotics
      • 7.1.1.2. Phenothiazine Antipsychotics
      • 7.1.1.3. Thioxanthenes
      • 7.1.1.4. Miscellaneous Antipsychotic Agents
  • 7.2. Latin America Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Hospital Pharmacies
      • 7.2.1.2. Drug Stores
      • 7.2.1.3. Retail Pharmacies
      • 7.2.1.4. E-Commerce
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Schizophrenia Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 7.3.1.2. Brazil Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.3.1.3. Mexico Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 7.3.1.4. Mexico Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.3.1.5. Argentina Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 7.3.1.6. Argentina Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.3.1.7. Rest of Latin America Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 7.3.1.8. Rest of Latin America Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Schizophrenia Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Atypical Antipsychotics
      • 8.1.1.2. Phenothiazine Antipsychotics
      • 8.1.1.3. Thioxanthenes
      • 8.1.1.4. Miscellaneous Antipsychotic Agents
  • 8.2. Middle East & Africa Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Hospital Pharmacies
      • 8.2.1.2. Drug Stores
      • 8.2.1.3. Retail Pharmacies
      • 8.2.1.4. E-Commerce
  • 8.3. Middle East & Africa Schizophrenia Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 8.3.1.2. GCC Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.3.1.3. South Africa Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 8.3.1.4. South Africa Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.3.1.5. Egypt Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 8.3.1.6. Egypt Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.3.1.7. Nigeria Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 8.3.1.8. Nigeria Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.3.1.9. Rest of Middle East & Africa Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 8.3.1.10. Rest of Middle East & Africa Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Manufacturer vs by Distribution Channel Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Johnson & Johnson Services, Inc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Bristol-Myers Squibb Company
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Otsuka Holdings Co., Ltd
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. AstraZeneca
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Sumitomo Dainippon Pharma Co., Ltd.
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Eli Lilly and Company
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Alkermes
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Vanda Pharmaceuticals
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. ALLERGAN
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Pfizer Inc.
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations